Dangerous Drugs Board

Also known as: DDB — the standard abbreviation · Lupon sa Mapanganib na Droga — the Filipino designation · The Board — the internal styling of Republic Act No. 9165's Article IX

Government

Definition

The Dangerous Drugs Board (DDB; Filipino: Lupon sa Mapanganib na Droga) is the Philippine government’s policy-making and strategy-formulating body on dangerous drugs, the inter-agency board placed under the Office of the President by Republic Act No. 9165 (Comprehensive Dangerous Drugs Act of 2002). (LawPhil — RA 9165) The Board predates the 2002 statute: it was created by Section 35 of Republic Act No. 6425, the Dangerous Drugs Act of 1972, approved March 30, 1972 — “There is hereby created a Dangerous Drugs Board” of nine members, three appointive and six ex-officio department secretaries — and the standard account records its establishment under the Office of the President on November 14, 1972, in the first months of martial law. RA 9165 then reconstituted and expanded it to seventeen members: three permanent members led by a chairman with the rank of secretary serving six years, twelve ex-officio members drawn from the departments and agencies of government, and two regular members — the Integrated Bar of the Philippines president and a non-governmental representative — with the NBI Director and PNP Chief as permanent consultants. (LawPhil — RA 6425, Wikipedia — Dangerous Drugs Board, LawPhil — RA 9165)

The Board’s function is policy, not operations: it formulates the national drug-control strategy, issues the board regulations that implement the statute, and runs the prevention side — drug-abuse prevention, training and information, treatment and rehabilitation programs, research and statistics — while enforcement and licensing are executed by its implementing arm, the Philippine Drug Enforcement Agency, the division of labor this wiki’s entry on that agency frames. (LawPhil — RA 9165, Wikipedia — Dangerous Drugs Board) Its regulatory output includes the rules under which controlled medicines are prescribed and dispensed — Board Regulation No. 1, Series of 2014, tying dangerous-drug prescribing to the S-2 license that this wiki’s PDEA S2 license entry documents — and its chairmanship has been held by figures including Juan Flavier, Teofisto Guingona Jr., Vicente Sotto III, and, since February 2025, Oscar F. Valenzuela in the current-status record. (Wikipedia — Dangerous Drugs Board)

Identities

Source Type	Identity
Wikipedia	Dangerous Drugs Board
Wikidata	Dangerous Drugs Board (Q48698543)
DBpedia	Dangerous_Drugs_Board
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings (LCSH)	Narcotic laws
MeSH	N/A
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	Dangerous Drugs Board Philippines RA 6425 1972 RA 9165 reconstitution seventeen members policy-making Office of the President board regulations chairman
ConceptNet	N/A
OpenCyc	N/A

Also Known As

DDB — the standard abbreviation
Lupon sa Mapanganib na Droga — the Filipino designation
The Board — the internal styling of Republic Act No. 9165’s Article IX

Examples and Analogies

A board of principals, not an operator: the DDB’s design puts the secretaries of Justice, Health, Defense, Finance, Labor, Interior, Social Welfare, Foreign Affairs, and Education around one table with the PDEA Director General — drug policy decided by the government’s own principals, while a single agency executes, the contrast this wiki’s PDEA entry frames from the enforcement side. (LawPhil — RA 9165)
Policy board as the statute’s regulatory layer: the board regulations — of which Board Regulation No. 1, s. 2014 is the example this wiki carries — are the rules practitioners actually meet; the statute sets the crimes, the Board sets the paperwork, the framing of this wiki’s Republic Act No. 9165 entry. (LawPhil — RA 9165)
A 1972 institution retooled in 2002: the Board survived the repeal of its founding statute — RA 9165 abolished the 1972 Act but reconstituted the Board larger — an institutional continuity through reconstitution rather than replacement. (LawPhil — RA 6425, LawPhil — RA 9165)
Verified organizational data:
Creation: Section 35, RA 6425 (approved March 30, 1972) — nine members: three appointive (chairman designated by the President, six-year term) and the Secretaries of Justice, National Defense, Health, Education, Finance, and Social Welfare ex officio; NBI Director permanent consultant (LawPhil — RA 6425)
Establishment: recorded as November 14, 1972, under the Office of the President — the article of record’s own infobox carries 1971, a variance noted below (Wikipedia — Dangerous Drugs Board)
Original functions (RA 6425, Sec. 36): promulgating rules, custody of seized drugs, education campaigns, research, the national treatment and rehabilitation program, statistics (LawPhil — RA 6425)
Reconstitution (RA 9165, Secs. 77–80): “policy-making and strategy-formulating body” under the Office of the President; seventeen members — three permanent (chairman with rank of secretary, six years; two with rank of undersecretary), twelve ex officio (the nine department secretaries, the CHED and National Youth Commission chairmen, and the PDEA Director General), two regular (IBP president and an NGO representative); NBI Director and PNP Chief permanent consultants; quorum of nine; a Secretariat under an Executive Director with the rank of undersecretary (LawPhil — RA 9165)
Chairmanship: twenty-four chairs across five decades — Clemente Gatmaitan (1972–1979, the first), Juan Flavier (1992–1995), Teofisto Guingona Jr. (1996–1998), Vicente Sotto III (2008–2009), Catalino Cuy (2018–February 2025), Oscar F. Valenzuela (February 2025– ) (Wikipedia — Dangerous Drugs Board)

Usage Scenarios

1. Researching Drug-Control Policy

The Board is the starting point of Philippine drug policy study: its enabling texts — RA 6425’s creation and RA 9165’s reconstitution — fix the national strategy function, and its board regulations are the primary sources of the regulatory regime. (LawPhil — RA 6425, LawPhil — RA 9165)

2. Administering Controlled-Medicine Access

The lawful traffic in scheduled medicines runs on the Board’s regulations — Board Regulation No. 1, s. 2014 governing prescribing and dispensing, the S-2 license regime this wiki’s PDEA S2 license entry documents — so clinicians, pharmacies, and hospitals work inside DDB rules daily. (LawPhil — RA 9165)

3. Studying Inter-Agency Boards under the Office of the President

The Board’s composition — secretaries sitting ex officio with undersecretary-rank representatives, a PDEA chief at the table, permanent consultants from the NBI and PNP — is the leading Philippine specimen of policy by board under presidential supervision. (LawPhil — RA 9165)

4. Prevention, Treatment, and Rehabilitation Programs

The prevention mandate — drug-abuse prevention, training and information, the treatment and rehabilitation program, and the research and statistics on which policy rests — is the Board’s own portfolio, distinct from enforcement. (Wikipedia — Dangerous Drugs Board)

5. Following the Current Board

The chairmanship of Oscar F. Valenzuela since February 2025 is the current-status record of the Board’s leadership, reported as documented for a serving official. (Wikipedia — Dangerous Drugs Board)

Strategies

Policy by principals: seating the departments whose portfolios touch the drug problem — justice, health, education, welfare, local government — commits the whole government to the Board’s strategy rather than a single agency’s. (LawPhil — RA 9165)
Regulation through board regulations: rather than amending the statute, the Board adjusts the regime by regulation — the instrument that produced Board Regulation No. 1, s. 2014 and its prescription-form rules — the layer this wiki’s RA 9165 entry calls the Act’s regulatory layer. (LawPhil — RA 9165)
Write the balance into policy: the statute’s own declaration — that people with “legitimate medical needs” must not be prevented from treatment — is the text under which the Board calibrates control against access, the balance documented on the prescribing side by this wiki’s PDEA S2 license entry. (LawPhil — RA 9165)
Data as the policy input: from RA 6425’s statistics mandate to the modern national surveys, the Board’s user-prevalence numbers are the official measurements against which drug-war claims are tested. (LawPhil — RA 6425, Wikipedia — Dangerous Drugs Board)

Security and Safety Measures

Custody of seized drugs: the original statute placed seized and confiscated drugs in the Board’s custody — the 1972 safeguard against evidence recycling that the modern chain-of-custody rules of RA 9165 now govern, as this wiki’s entry on that statute documents. (LawPhil — RA 6425, LawPhil — RA 9165)
Quorum and delegation discipline: a nine-member quorum of seventeen, weekly meetings, and a Secretariat under an undersecretary-rank executive director keep the Board’s decisions collective and recorded. (LawPhil — RA 9165)
Anti-diversion by licensing: the S-2/S-3 licensing paper trail administered at the Board’s direction makes every lawful transaction traceable to a licensed custodian — the security design this wiki’s PDEA S2 license entry describes. (LawPhil — RA 9165)
For researchers: two date conventions recur — the 1971-versus-1972 establishment of the Board in the article of record’s own infobox and text, and the March 30, 1972 approval date of RA 6425 against the Act’s April publication convention — cite the statutory approval date and note the variance openly. (LawPhil — RA 6425, Wikipedia — Dangerous Drugs Board)

Historical Context

The Board was born of the 1972 statute that gave the Philippines its first comprehensive drug law. RA 6425 — approved March 30, 1972, when the standard account estimated some 20,000 drug users and marijuana was the most-used illegal drug — created a nine-member board of appointive experts and department secretaries to make policy, take custody of seizures, and build the treatment and research programs; the standard account records its establishment under the Office of the President on November 14, 1972, after martial law had been declared in September. For three decades the Board operated under the 1972 Act while the drug market it regulated — above all the methamphetamine economy — outgrew the law’s framework. (LawPhil — RA 6425, Wikipedia — Dangerous Drugs Board)

RA 9165 replaced the statute and kept the institution: the Board reconstituted as the policy-making and strategy-formulating body under the Office of the President, expanded to seventeen members with the new PDEA Director General at its table as both member and implementing arm. Its chairmanship has since run through figures including Angelo Reyes, Anselmo Avenido Jr. (who had been PDEA’s first Director General), Vicente Sotto III, Catalino Cuy, and Oscar F. Valenzuela since February 2025, while its regulatory output — from board regulations to the prescription-form rules — and its survey data have made it both the administrative backbone of lawful drug control and the reference point in the drug-war era’s statistical disputes, the role examined below. (LawPhil — RA 9165, Wikipedia — Dangerous Drugs Board)

Challenges and Controversies

The User-Number Dispute

The Board’s survey figures — on the order of 1.8 million users — stood against the presidential claims of three million or more drug addicts cited at the drug war’s launch, a gap between the policy board’s statistics and the campaign’s premises that was never resolved; the Board’s data remain the official measurement and the campaign’s arithmetic the political one. (Wikipedia — Dangerous Drugs Board)

Policy Board or Operational Overlap?

The statutory division — the Board decides, PDEA executes — has been blurred in practice by the scale of police-led enforcement and by inter-agency committees chaired elsewhere, leaving the Board’s authority more complete on paper than in campaign direction, the institutional question this wiki’s PDEA and RA 9165 entries document. (LawPhil — RA 9165)

Licensing Friction and Medical Access

The Board’s regulations — prescription-form rules, licensing requirements, drug-testing of prescribers — are defended as RA 9165’s security and criticized as friction on patients and clinicians; the 2025 interim rule allowing ordinary triplicate prescriptions, documented in this wiki’s PDEA S2 license entry, is the recurring recalibration. (LawPhil — RA 9165)

The Establishment-Date Variance

The article of record’s own text dates the Board’s establishment November 14, 1972 while its infobox carries 1971 — a small but persistent variance, resolved for citation purposes by anchoring to the statutory creation in RA 6425 and noting the discrepancy rather than choosing one date silently. (LawPhil — RA 6425, Wikipedia — Dangerous Drugs Board)